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Abstract 
 
Aims 
Benefits of routine depression screening for cardiometabolic disease patients remain unclear.  
We examined the association between depression screening and all-cause mortality and 
vascular events in cardiometabolic disease patients.  
 
Methods and Results 
125143 patients with cardiometabolic diseases (coronary heart disease, diabetes or previous 
stroke) in United Kingdom participated in primary care chronic disease management in 
2008/09, which included depression screening using the Hospital Anxiety and Depression 
Score. 10670 receiving depression treatment exempted, 35537 screened, while 78936 not 
screened. We studied all-cause mortality and vascular events at four years,  by electronic data 
linkage of 124414 patients (99·4%) on primary care registers to hospital discharge and 
mortality records and used Cox proportional hazards on matched data using propensity score. 
 
Mean age for the screened and not screened population was 69 years (standard deviation-SD 
11·9) and 67 years (SD 14·3), respectively; 58% (20658) of the screened population were 
men and 65·3% (22726) were socioeconomically deprived, compared with 54·2 % (42727) 
and 67·4% (51686), respectively, in the not screened population. The screened population 
had lower all-cause mortality (Hazard Ratio-HR 0.89) and vascular events (HR0.85) in the 
matched data of N=21893 patients each in the screened and the unscreened groups.   
 
Conclusion 
Depression screening was associated with a reduction in all-cause mortality and vascular 
events in patients with cardiometabolic diseases. The uptake of screening was poor for 
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unknown reasons. Reverse causality and confounding by disease severity and quality of care 
are important possible limitations. Further research to determine reproducibility and explore 
underlying mechanisms is merited.  
 
Key Words: Depression; Coronary Heart Disease; Diabetes Mellitus; Stroke; Cardiovascular 
Complications.   
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Introduction 
 
Patients with cardiometabolic diseases such as coronary heart disease (CHD), diabetes and 
stroke, depression prevalence is estimated to be 15-25% (1–3). Co-morbid depression in 
patients with cardiometabolic disease is associated with increased mortality, worse 
cardiovascular outcomes and poor functional outcomes (2,4,5).  
 
Considering the increased prevalence and associated complications, the American Heart 
Association Science Advisory panel has recommended routine depression screening for all 
patients with CHD since 2008 (6). However, there is no evidence to date that routine 
depression screening for patients with cardiometabolic disease leads to any improvement in 
depression or cardiac outcomes (7,8). Two recently published systematic reviews did not find 
a single randomized trial evaluating the efficacy of depression screening as a standalone 
intervention in patients with cardiometabolic disease (7,8). Most of the evidence in this area 
has come from trials evaluating the benefits of depression screening as a part of a wider 
intervention, which also involved management of depressive symptoms (7,8).  These trials 
have not found any evidence of improvements in mortality or cardiovascular outcomes with 
comprehensive interventions involving depressions screening and its management in patients 
with cardiometabolic disease (7,8). There is some evidence to suggest that collaborative care 
models, which usually include depression screening and comprehensive patient management, 
lead to improvement in depressive symptoms and glycaemic control (in patients with 
diabetes) but no evidence of reduction in cardiovascular outcomes (9,10).   
 
 In the UK, NICE (National Institute for Health and Care Excellence) recommends that 
depression screening or ‘case finding’ in patients with chronic disease should only be 
targeted towards those who are believed to be ‘high risk’ (11). The UK Quality and 
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Outcomes Framework (QOF), an annual reward and incentive programme for primary care, 
offered financial incentives to primary care practitioners for routine depression screening for 
all patients with coronary heart disease and diabetes, between 2006/07 and 2013/14 (12). 
These financial incentives have been withdrawn from the QOF programme since 2013/14 
(13).  However the potential role of standalone depression screening for all patients with 
cardiometabolic disease, as an intervention to identify those patients with depression but 
without specific management interventions, in reducing adverse outcomes related to physical 
health remains unclear. The aim of this project was to study the association, if any, between 
depression screening in patients with three cardiometabolic conditions, namely, stroke, 
diabetes and CHD and the rates of general hospital admissions, mental health unit 
admissions, cardiovascular outcomes and mortality at the end of four years follow-up . 
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Methods 
Study Design and Setting 
The data reported in this paper came from two different health boards in the West of Scotland 
who serve a population of circa 1.8 million. We received approval from the National 
Research Ethics Service (NRES), NHS Scotland Privacy Advisory Committee (PAC) NHS 
Greater Glasgow and Clyde Enhanced Services data group to undertake this work. The work 
involved retrospective analysis of a large routinely collected dataset which was completely 
annonymised and the research team did not have access to patient identifiers, hence 
individual patient consent was not obtained.  
 
The local health boards oversaw a programme of incentivised depression screening in chronic 
disease as part of a wider chronic disease management programme of ‘Local Enhanced 
Services’ (LES). These are contractual arrangements at a local health board level with family 
practices designed to augment the basic QOF specification by incentivising additional 
indicators that are deemed to be particularly important for the local setting.  There were no 
penalties for non-adherence. General practices in the health boards studied were paid under 
the LES scheme to carry out a comprehensive annual health assessment, which included 
depression screening, for all patients with one of the three common cardiometabolic 
conditions, CHD, diabetes and stroke. The annual health assessment was usually carried out 
by a practice nurse and lasted approximately one hour.  Depression screening was part of the 
health assessment for all patients apart from those recognised to be ‘under treatment’ for 
depression at the time of their health assessment. Patients who were found to have a positive 
result on depression screening were offered treatment based on routine care for management 
of depressive symptoms based on national guidelines. 
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Participants 
We restricted our analysis to adults aged from 18 to 90 who had a health assessment recorded 
for at least one of the three conditions between 01/04/2008 to 31/03/2009. A total of 125,143 
patients were listed as having CHD, diabetes or stroke in the year 2008-09, the “DepChron” 
dataset, all of these patients underwent a comprehensive health assessment as part of LES 
(14,15).   The definition of cardiometabolic condition (diabetes, stroke and CHD) and patient 
eligibility were based on the respective general practice register for these conditions. The 
general practice register did not take disease duration in to account while considering 
eligibility. Patients were labelled as ‘under treatment’ for depression and exempt from 
depression screening if they were noted to be on antidepressants (excluding amitriptyline) 
based on their prescription record (14,15). This strategy was used for defining patients under 
treatment for depression as opposed to diagnostic codes as the use of diagnostic codes for 
recording depression by GPs in the UK has been reported to be low (16).   
 
Measurement of Clinical Variables 
The exposure of depressions screening was defined on the basis of recording of depressive 
subscale of Hospital Anxiety and Depression Scale (HADS-D) (17). The HADS-D gives a 
total score of 0 to 21 (17), and a threshold of  >7 was used to define the presence of 
depressive symptoms, as endorsed by national guidelines (18). The area based Scottish Index 
of Multiple Deprivations (SIMD) was used as a measure of socioeconomic status with 
patients categorised into deciles of deprivation relevant to the Scottish population (19). 
Smoking status was divided into current non-smokers and smokers; alcohol status was 
classified into moderate (< 21 units men, <14 units women), hazardous (21-50 units men, 14-
35 units women) and harmful (>50 units men, >35 units women) based on their weekly units 
consumption (20). We checked for a new prescription of antidepressants for the duration of 
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the observation period for the not screened patients and for six months after the date of 
screening for the screened patients; we excluded amitriptyline as it is often used in the 
management of chronic pain in primary care. No reliable information was available on the 
number of patients who were referred for psychological therapies following their depression 
screening.  
 
Measurement of Outcome Variables 
We electronically linked the health records for patients on primary care registers with 
hospitalization and mortality records held by the Information Services Division (ISD), 
Scotland from April 2009 to March 2013. We studied six different outcomes for using the 
International System of Disease Classification- 10
th
 Edition (ICD-10) codes for diagnostic 
accuracy (21). The outcomes studied included all-cause mortality, all-cause hospital 
admissions, cardiovascular disease (CVD) related mortality, CVD related hospital 
admissions, psychiatry unit admissions and new vascular events (myocardial infarction-MI 
and stroke incidence).  
 
Statistical Analysis 
Time to event analysis was performed to compare the six adverse clinical outcomes between 
the screened and the not screened population.  Kaplan-Meier style plots were used to initially 
visualise the results for each clinical outcome, unadjusted for covariates, to evaluate the 
benefits of depression screening with the not screened group as the reference category. 
 
We performed a propensity score matching analysis to assess the impact of depression 
screening when accounting for factors that influenced whether a patient was screened. A 
propensity score is the probability that an individual would be assigned to a group, given a set 
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of covariates. We used stepwise selection logistic regression to produce the predicted 
probability (propensity score) that an individual belongs to the screened or non-screened 
group base The method of matching patients in the screened and un-screened groups was 
based on matching on an allowable absolute difference between exact propensity scores. This 
score was obtained from a logistic regression model for the probability that a patient would 
have been screened. The screened and un-screened patients were matched 1:1 where the 
absolute difference between their scores was +/- 0.01. All the individual predictors included 
in the model were forced to stay in whether significant or not. See Supplement 1 for the SAS 
output from the logistic regression model. 
 
We included the following predictors and their pairwise interaction in the logistic regression 
models: sex, age, SIMD (quintiles), antidepressant initiation, number of co-morbidities, 
alcohol consumption, history of diabetes, body mass index group, smoking status, ethnicity, 
systolic blood pressure (BP), diastolic BP, cholesterol, fasting glucose, random glucose, pulse 
rate, estimated glomerular filtration rate, Hba1c and serum creatinine. The continuous 
variables were centred on their mean and missing values replaced with zero. For each 
continuous variable, with the exception of age which has very low missing, we included a 
dummy variable with missing yes or no.  The resulting matched data was used to produce the 
Cox’s proportional hazards regression stratified by the matched pairs and the hazard ratios 
from the matched data was compared between the depression screened and the unscreened 
group. 
 
We also performed univariable and multivariable analysis to compare the rate of adverse 
clinical outcomes between patients with depression screen positive (HADS-D>7) and those 
with depression screen negative. The multivariable analysis was adjusted for the covariates 
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age, sex, SIMD, multimorbidity and the initiation of antidepressants. Age (18-29, 30-49, 50-
69, 70-89), sex (male and female) socio-economic status (SIMD quintiles 1-5) and initiation 
of antidepressants (yes/no) were entered into all of the models as binary variables. Number of 
comorbid conditions (range 1-3, representing a combination of one or more of the three 
cardiometabolic disease under investigations: CHD, stroke or diabetes) was entered into all 
regression models as an ordinal variable. Smoking status and alcohol consumption variables 
were excluded from regression models due to high missing values.  
 
Analysis was carried out using the R statistical software, version 3.0.2 and SAS, version 9.3 
by SAS Institute Inc., Cary, NC, USA.   
 
Sensitivity analysis 
We performed a sub-group analysis to measure the interaction effect of different 
demographic and clinical variables with depression screening. We compared the rate of the 
six adverse clinical outcomes between the screened and non-screened patients in five 
different sub-groups based on age, sex, socioeconomic status, number of cardiometabolic 
comorbidities and initiation of antidepressants. These results were visualised using a forest 
plot.  
 
We also performed an additional sensitivity analysis in patients who had results of both 
smoking and alcohol consumption recorded, and compared outcomes between the depression 
screened and the non-screened groups.  
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Results 
Sample Size, Characteristics and Clinical Outcomes 
A total of 125,143 patients were recorded to have at least one of the three cardiometabolic 
diseases, CHD, diabetes and previous stroke, and they all underwent comprehensive health 
assessment. Of the total sample, 10670 (8.5%) patients were ‘under treatment’ for depression 
and were thus exempt from screening. The remaining 114473 (91.5% of total sample size) 
patients were all eligible for depression screening. However, depression screening was only 
recorded in 35537 (31.1% of those eligible) of those undergoing the annual health assessment 
and 78936 (68.9%) of those assessed were not screened for depression (see Figure 1). 6.3% 
(4989/78936) of the not screened population were started on new antidepressants during the 
observation period (with no clear explanation recorded), whereas 3.6% (1268/35537) of the 
screened population were started on new antidepressants within six months of depression 
screening.  Electronic data linkage between primary care disease registers and hospital 
discharge and mortality records was successful for 99.4% (124414/125143) of patients. The 
demographic features, distribution of clinical variables and the absolute number of adverse 
clinical outcomes for the screened and not screened population are compared in Table 1. 
 
Among the patients who had recorded results of depression screening, 7080/35537 (19.9%) 
were identified as screen positives based on HADS-D >7 (see Figure 1). New antidepressants 
were initiated for 2.4% (696/28457) of patients with HADS-D negative and 8.1% (572/7080) 
of patients with HADS-D positive within six months of depression screening. The median 
duration of follow-up was 210 weeks. At the end of 4 years follow-up period, the overall 
mortality rate was 16.2% (18590/114473).  Table 2 compares the demographic features, 
clinical variables distribution and the absolute number of adverse clinical outcomes for 
HADS-D positive and HADS-D negative patients. 
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Comparison of Clinical Outcomes between Depression Screened and Not Screened Patients 
Figure 2 shows a panel of Kaplan-Meier plots for all of the six adverse clinical outcomes 
studied for the two patient groups. As shown in the figure, the screened group did better in all 
clinical outcomes apart from all-cause hospital admissions, which were similar for both the 
groups.  
 
As a result of propensity score matching, N=21893 patients each in the depression screened 
and the unscreened group were matched for 19 demographic, behavioural and clinical patient 
characteristics (see Table 3). Cox proportional hazards regression on the matched data 
showed that the screened group had lower risk than the not screened group for all of the six 
clinical outcomes studied at the end of the four year observation period (see Table 4).  
 
Comparison of Clinical Outcomes between Depression Screen Positive (HADS-D>7) and 
Screen Negative Patients  
The panel of Kaplan-Meier plots in Figure 3 shows that patients with a negative depression 
screen did better in all six clinical outcomes under study at the end of four years.  
 
The screen positive groups (HADS-D mild 8-10, moderate to severe 11-21) had higher risk 
for all adverse clinical outcomes when compared to the screen negative group in the 
unadjusted analyses using the Cox proportional hazards. The risk for screen positives 
compared to screen negatives was unmitigated after adjusting for age, sex, socioeconomic 
deprivation, number of cardiometabolic comorbidities and antidepressant initiation (Table 5).  
 
Among the 1268 patients among depression screened who were treated with initiation of 
antidepressants, the adjusted HR for all-cause mortality was not significantly different for the 
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mild depression group (HR 0.89, CI 0.57- 1.37) and the moderate/severe depression group 
(HR 1.33, CI 0.85-2.08), when compared to the screening negative group.  
 
Sensitivity Analysis 
In the sub-group analyses for different patient groups, comparing the clinical outcomes for 
the depression screened and not screened patients, screened patients had better outcomes in 
the sub-group analyses based on age, sex and socioeconomic status (see Figure 4). For the 
sub-group of patients who were initiated on new antidepressants, the confidence crossed the 
significance line for all-cause hospital admissions, cardiovascular disease related hospital 
admissions and psychiatry unit admissions. This implies that there was no statistically 
significant difference for these three clinical outcomes between the screened and the not 
screened patients who were initiated on antidepressants. Similarly, for the sub-group of 
patients with all three cardiometabolic conditions, there was no statistically significant 
difference between the screened and the not screened group for all-cause hospital admissions, 
psychiatry unit admissions, incidence of stroke/MI and CVD related hospital admissions.  
 
In the subset of patients who had results of smoking and alcohol consumption recorded 
(22068/114473), the trends in results of better clinical outcomes in the depression screened 
group was unchanged, after additionally adjusting for smoking and alcohol consumption (see 
supplement 1).  
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Discussion 
Summary of Findings 
In a large, community based sample of patients with CHD, previous stroke, or diabetes, 
depression screening was associated with reduced risk at four years of: all-cause mortality; 
CVD related mortality; CVD related hospital admissions; psychiatry unit admissions; and 
new vascular events, in matched data analysis using propensity score methods. Patients who 
had a positive result on depression screening were also significantly more likely to 
experience increased risk of these same adverse clinical outcomes. These associations 
remained significant after adjusting for demographic factors such as age, sex and socio-
economic status; and clinical factors such as number of cardiometabolic conditions and 
initiation of antidepressants.  
 
Patients who were not screened for depression were more likely to be initiated on new 
antidepressants when compared to the screened patients as a whole but less likely when 
compared to those who had a positive result on depression screening. 
   
Strengths and Limitations 
This study has a number of key strengths, in that the data came from a large, community 
based sample reflecting real life clinical practice and  electronic data linkage enabled 
successful follow-up for the majority of patients in the cohort. There are several limitations. 
In this large, community based sample of patients with CHD, previous stroke, or diabetes  
only a minority had depression screening recorded  despite incentivisation. Since only a 
minority of the patients were actually screened, there may be important differences between 
patients with known depression status and those whose depression status was unknown, 
which are not clearly evident from their baseline demographic data. There is a possibility that 
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the observed association is due to confounding as patients in this study were not randomly 
allocated to the screened and unscreened groups. For example, practitioners may intuitively 
screen patients where they are more likely to get a positive result, for instance patients with 
severe disease or multimorbidity. Also, there is a possibility of reverse causality with GPs 
reviewing a patient whom they consider to have depression and offering screening 
subsequently. Previously reported barriers to discussing depression (or mental health) in 
patients with chronic disease in primary care, such as stigma associated around the ‘label’ 
and physicians’ preconception of normalizing depression in patients with chronic disease, 
could also be influencing factors behind low uptake of depression screening in our study 
(22,23).  Additionally, patients with other psychiatric co-morbidities such as dementia or 
psychoses who are at higher risk of co-morbid depression may have been excluded from 
depression screening by the GP and may have been in the unscreened group. This could be 
one of the reasons for the higher observed rate of new antidepressants prescribing in the 
unscreened group as compared to the screened group.  
 
In addition, the rate of data completion was better in the screened population than the 
unscreened population, which may be a marker of better quality of care received by the 
screened population, and in turn may have contributed to the observed difference in clinical 
outcomes between the two groups. For example, the information on blood pressure 
measurement and smoking consumption was available for 69.9% (55198/78936) and 32.3% 
(25554/78936) respectively for the unscreened group.  In comparison, the information on 
blood pressure measurement and smoking consumption was available for 90.4% 
(32139/35537) and 42.4% (15092/35537) respectively for the depression screen group. 
Among those patients who did not have a diagnosis of diabetes at the time of data collection, 
blood glucose measurement is recommended as a screening test for diabetes (13). Blood 
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glucose measurement was performed for 22.6% (9187/40576) patients without diabetes in the 
unscreened population; while it was performed for 59.9% (10237/17084) patients without 
diabetes in the screened population. Among patients with diabetes, HbA1c was recorded for 
57.8% (22180/38360) patients in the unscreened group as compared to 84.9% (15678/18453) 
patients in the depression screened group. The only exception was the results recording for 
alcohol consumption, which was better for the unscreened group.  
 
Secondly, we did not have information on disease severity or disease duration for the patients 
in the cohort. The information on cardiac medications was missing as well. These factors are 
likely to have influenced the clinical outcomes considered in our study.  
 
Thirdly, information on psychosocial treatment options offered to the patients in our cohort 
was not available. However, there is no evidence to date that psychosocial therapies in the 
treatment of depression in patients with cardiometabolic disease has any beneficial effect on 
cardiovascular disease related physical outcomes or mortality (24–26). The overall rate of 
antidepressant initiation was higher for the unscreened 6.3% (4989/78936) when compared to 
those who were screened for depression 3.6% (1268/35537). This may suggest a possibility 
of bias against depression screening in the subset of patients who were apparently treated for 
depression with antidepressants but not screened for depression.  
 
Fourthly, we did not have any information on health care utilization over the observation 
period, such as frequency of visits to family practitioner and involvement with secondary care 
services such as cardiac rehabilitations team. These factors are likely to have influenced the 
clinical outcomes considered in this study.  
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Finally, the overall accuracy of depression screening in our study was reliant on HADS-D 
which is a self-reported measure and has various drawbacks when used for assessing 
depressive symptoms in patients with cardiometabolic disease in a primary care setting 
(18,27,28). There are some other self-reported measures for depression screening, such as the 
Patient Health Questionnaire (PHQ-9) and Beck’s Depression Inventory (BDI), which have 
been found to have a better overall diagnostic accuracy in patients with cardiometabolic 
disease(18,27,28).  
 
Comparison with existing literature 
The rate of positive screens identified as a result of depression screening in our study of 
routine practice was 19.9% which is within the range of rates of 6-22% reported in clinical 
trials (7) and rates of 2 to 20% in epidemiological studies (29,30). In our study, patients with 
positive depression screening were more likely to have adverse outcomes, this is consistent 
with previous evidence which shows increased risk of mortality and cardiovascular related 
outcomes in patients with depression co-morbid with CHD (31), diabetes(32) and history of 
previous stroke (33).  The potential influence of antidepressant prescribing on the findings of 
our study remains unclear. The Cochrane reviews on patients with CHD (24) and diabetes 
(25) have found no benefits of treating depressive symptoms with antidepressants on 
reducing all-cause mortality and cardiovascular related complications. For stroke patients, the 
evidence is very little with only one trial in patients with post stroke depression finding 
improvement in all-cause mortality for up to 9 years of follow-up with 8 weeks of 
antidepressants treatment compared against placebo (34).  
 
Implication of Findings 
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The American Heart Association has issued a scientific statement in 2014 suggesting that 
depression should be considered a risk factor for poor prognosis in patients with acute 
coronary syndrome; however clinical implications for detecting and managing co-morbid 
depression in patients with cardiometabolic disease remains unclear (35). In patients with 
cardiometabolic diseases, to date, there has been no evidence that depression screening 
offered as a part of a wider intervention in randomized controlled trials evaluating depression 
management, leads to improvements in all-cause mortality and cardiovascular related 
outcomes. If the observed association between depression screening and improvement in 
cardiovascular outcomes, mortality and all cause admissions is true, it has important 
implications for the management of cardiometabolic disease. There may be potential benefits 
from depression screening in cardiometabolic disease, especially in patients at high risk, and 
further research is needed in this area.  
 
Conclusion 
In a general practice sample of patients with CHD, stroke, or diabetes, depression screening 
was associated with improvements in all-cause mortality, cardiovascular related outcomes 
and psychiatry unit admissions at four years. There is a possibility that these results could be 
explained by residual confounding from unknown differences in disease severity, quality of 
care and health care utilization. Further research is necessary to determine whether these 
results are replicable using other datasets; to investigate the nature of the observed 
relationship; and increase understanding of the mechanisms underpinning these effects. 
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Figure 1 Title: Study sample size and recruitment.  
 
Legend: HADS=Hospital Anxiety and Depression Score. 
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Figure 2 Title: Kaplan-Meier plots comparing clinical outcomes between depression 
screened and the not screened patient groups in existing cardiometabolic disease.  
 
Legend: A panel of six plots for six different clinical outcomes comparing cumulative 
incidence for the depression screened and the not screened patient groups.  
 
 
 
 
 
 
 
 
 
25 
 
Figure 3 Title: Kaplan-Meier plots comparing clinical outcomes between HADS-D 
positive and HADS-D negative patient groups in existing cardiometabolic disease.  
 
Legend: A panel of six plots for six different clinical outcomes comparing cumulative 
incidence for the depression screened and the not screened patient groups.  
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Figure 4 Title: Subgroup analyses for clinical outcomes for depression screened and the 
not screened patient groups in existing cardiometabolic disease.  
 
Legend: A panel of six forest plots for six different clinical outcomes. If a line for an 
individual patient subgroup crosses the line of significance (1), it implies that the difference 
in outcome is not statistically significant for that particular subgroup of patients. 
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Table 1 Title: Comparison of depression screened and the not screened patient groups 
in existing cardiometabolic disease.   
 Depression Screened  
N= 35537 
Not Screened  
N=78936 
p-
value 
Age(years) - mean (SD), n                                    69.0 (11.9), 35526 67.0 (14.3), 78905 <0.001 
White ethnicity-n/N (%)                                       30693/33214 (92.4) 53343/59043 (90.3) <0.001 
Male sex - n/N (%)                                  20658/35519 (58.2) 42727/78889 (54.2) <0.001 
Deprived socio-economic status SIMD 
deciles<=5 -n/N (%)                              
22726/34805 (65.3) 51686/76740 (67.4) <0.001 
Alcohol consumption - n/N (%)                                   
              Moderate 
              Hazardous 
              Harmful 
30367/31471 (96.5) 
988/31471 (3.1) 
116/31471 (0.4) 
19469/20338 (95.7) 
724/20338 (3.6) 
145/20338 (0.7) 
<0.001 
Smoking Status - n/N (%)                                        
Non-smokers  
Current smokers                                                
9907/15092 (65.6) 
5185/15092 (34.4) 
15510/25554 (60.7) 
10044/25554 (39.3) 
<0.001 
Number of co-morbidities - n/N (%)                              
      One  
      Two  
     Three  
27356/35537 (77.0) 
7410/35537 (20.9) 
771/35537 (2.2) 
65417/78936 (82.9) 
12265/78936 (15.5) 
1254/78936 (1.6) 
<0.001 
Antidepressant initiation -n/N (%)                           1268/35537(3.5) 4989/78936 (6.3) <0.001 
All-cause mortality -n/N (%)                                                5021/35537 (14.1) 13569/78936 (17.2) <0.001 
New vascular events (Stroke/MI 
incidence) -n/N (%)                          
2068/35537 (5.8) 6193/78936 (7.8) <0.001 
All-cause hospital admissions -n/N (%)                        23717/35537 (66.7) 52089/78936 (66.0) 0.013 
Cardiovascular disease related hospital 
admissions -n/N (%)                                
6701/35537 (18.9) 16278/78936 (20.6) <0.001 
Psychiatry unit admissions -n/N (%)                        203/35537 (0.6) 866/78936 (1.1) <0.001 
Cardiovascular disease related 
mortality- n/N (%) 
1734/35537 (4.8%) 4823/78936 (6.1%) <0.001 
 
Legend: SIMD=Scottish Index of Multiple Deprivation SD= Standard Deviation.  
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Table 2 Title: Comparison of HADS-D positive and HADS-D negative patient groups in 
existing cardiometabolic disease.   
 HADS-D Positive  N= 
7080 
HADS-D Negative 
N=28457 
p-
value 
Age(years) - mean (SD), n                                    66.89 (12.36), 7077 69.56 (11.72), 28449 <0.001 
White ethnicity-n/N (%)                                       5953/6534 (91.1) 24740/26680 (92.7) <0.001 
Male sex - n/N (%)                                  3900/7072 (55.1) 16758/28447 (58.9) <0.001 
Deprived socio-economic status SIMD 
deciles<=5 -n/N (%)                              
5332/6917 (77.1) 17394/27888 (62.4) <0.001 
Alcohol consumption - n/N (%)                                   
              Moderate 
              Hazardous 
              Harmful                         
5628/5853 (96.2) 
184/5853 (3.1) 
41/5853 (0.7) 
24739/25618 (96.6) 
804/25618 (3.1) 
75/25618 (0.3) 
<0.001 
Smoking Status - n/N (%)                                        
Non-smokers 
Current smokers                                                 
1901/3582 (53.1) 
1680/3582 (46.9) 
8005/11510 (69.5) 
3505/11510 (30.5) 
<0.001 
Number of co-morbidities - n/N (%)                              
      One  
      Two  
     Three  
5095/7080 (72.0) 
1781/7080 (25.2) 
204/7080 (2.9) 
22261/28457 (78.2) 
5629/28457 (19.8) 
567/28457 (2.0) 
<0.001 
Antidepressant initiation -n/N (%)                           572/7080 (8.1) 696/28457 (2.4) <0.001 
All-cause death -n/N (%)                                                1244/7080 (17.6) 3777/28457 (13.3) <0.001 
New vascular events (Stroke/MI 
incidence) -n/N (%)                          
486/7080 (6.9) 1582/28457 (5.6) <0.001 
All-cause hospital admissions -n/N 
(%)                        
5184/7080 (73.2) 18533/28457 (65.1)  <0.001 
Cardiovascular disease related hospital 
admissions -n/N (%)                                
            1538/7080 (21.7) 5163/28457 (18.1) <0.001 
Psychiatry unit admissions -n/N (%)                         66/7080 (0.9) 137/28457 (0.5) <0.001 
Cardiovascular disease related 
mortality- n/N (%) 
398/7080 (5.6%) 1336/28457 (4.6%) <0.001 
 
Legend: HADS-D= Hospital Anxiety and Depression Score-depressive subscale HADS-D 
positive=HADS-D>7.SIMD=Scottish Index of Multiple Deprivation. SD= Standard 
Deviation.  
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Table 3 Title: Comparison of demographic, behavioural and cardiovascular factors in 
depression screened and not screened patient groups in existing cardiometabolic disease 
for the matched data.   
Patient 
Characteristics 
 Screened - N =  21893 Non-Screened - N =  
21893 
p-
value 
Sex Missing/Total (%) 13/21893 (0.1) 12/21893 (0.1) 0.84 
 Male 12068/21880 (55.2) 12047/21881 (55.1)  
 Female 9812/21880 (44.8) 9834/21881 (44.9)  
Age (years) Missing/Total (%) 6/21893 (0.03 %) 8/21893 (0.04 %) 0.62 
 Mean (SD) 67.9 (12.4) 67.8 (12.9)  
 Median (IQR) 69.0 (60.0 to 77.0) 70.0 (59.0 to 78.0)  
 Min - Max 18.0 - 90.0 18.0 - 90.0  
Body mass 
index (kg/m2) 
Missing/Total (%) 4603/21893 (21.02 %) 4652/21893 (21.25 %) 0.09 
 Mean (SD) 29.0 (6.1) 29.0 (6.2)  
 Median (IQR) 28.1 (24.9 to 32.1) 28.3 (24.9 to 32.2)  
 Min - Max 5.9 - 96.0 12.5 - 99.0  
BMI missing Yes 4603/21893 (21.0) 4652/21893 (21.2) 0.57 
 No 17290/21893 (79.0) 17241/21893 (78.8)  
SIMD 
(quintiles) 
No 470/21893 (2.1) 492/21893 (2.2) 0.89 
 1 = Most deprived 9271/21423 (43.3) 9256/21401 (43.3)  
 2 4087/21423 (19.1) 4062/21401 (19.0)  
 3 2614/21423 (12.2) 2617/21401 (12.2)  
 4 2383/21423 (11.1) 2403/21401 (11.2)  
 5 = Least 
deprived 
3068/21423 (14.3) 3063/21401 (14.3)  
Antidepressant 
initiation 
Yes 1222/21893 (5.6) 1244/21893 (5.7) 0.65 
 No 20671/21893 (94.4) 20649/21893 (94.3)  
Number of co-
morbidities 
One 16972/21893 (77.5) 16939/21893 (77.4) 0.45 
 Two 4450/21893 (20.3) 4444/21893 (20.3)  
 Three  471/21893 (2.2) 510/21893 (2.3)  
History of Yes 11938/21893 (54.5) 11967/21893 (54.7) 0.78 
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Diabetes 
 No 9955/21893 (45.5) 9926/21893 (45.3)  
Smoking 
Status 
No 12994/21893 (59.4) 13079/21893 (59.7) 0.89 
 Ex-smoker 5307/8899 (59.6) 5287/8814 (60.0)  
 Current Smoker 3507/8899 (39.4) 3442/8814 (39.1)  
 Non-smoker 85/8899 (1.0) 85/8814 (1.0)  
Systolic BP 
(mmHg) 
Missing/Total (%) 1984/21893 (9.06 %) 2073/21893 (9.47 %) 0.99 
 Mean (SD) 133.7 (17.9) 133.7 (18.2)  
 Median (IQR) 132.0 (121.0 to 143.0) 132.0 (120.0 to 142.0)  
 Min - Max 60.0 - 228.0 55.0 - 244.0  
SBP Missing Yes 1984/21893 (9.1) 2073/21893 (9.5) 0.14 
 No 19909/21893 (90.9) 19820/21893 (90.5)  
Diastolic BP 
(mmHg) 
Missing/Total (%) 1984/21893 (9.06 %) 2073/21893 (9.47 %) 0.12 
 Mean (SD) 75.3 (10.5) 75.3 (10.5)  
 Median (IQR) 76.0 (70.0 to 80.0) 76.0 (70.0 to 80.0)  
 Min - Max 30.0 - 131.0 38.0 - 135.0  
Cholesterol 
(mmol/l) 
Missing/Total (%) 2913/21893 (13.31 %) 2917/21893 (13.32 %) 0.86 
 Mean (SD) 4.4 (1.1) 4.4 (1.1)  
 Median (IQR) 4.2 (3.7 to 4.9) 4.2 (3.6 to 5.0)  
 Min - Max 1.1 - 14.5 1.0 - 14.2  
Cholesterol 
missing 
Yes 2913/21893 (13.3) 2917/21893 (13.3) 0.96 
 No 18980/21893 (86.7) 18976/21893 (86.7)  
Fasting 
glucose 
(mmol/l) 
Missing/Total (%) 18179/21893 (83.04 
%) 
18170/21893 (82.99 
%) 
0.88 
 Mean (SD) 7.4 (3.3) 7.4 (3.4)  
 Median (IQR) 6.4 (5.3 to 8.3) 6.3 (5.3 to 8.2)  
 Min - Max 1.9 - 28.9 1.0 - 30.0  
Fasting 
glucose 
missing 
Yes 18179/21893 (83.0) 18170/21893 (83.0) 0.91 
 No 3714/21893 (17.0) 3723/21893 (17.0)  
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Random 
glucose 
(mmol/l) 
Missing/Total (%) 14984/21893 (68.44 
%) 
14948/21893 (68.28 
%) 
0.64 
 Mean (SD) 7.9 (4.4) 7.9 (4.3)  
 Median (IQR) 6.2 (5.2 to 9.0) 6.2 (5.2 to 8.9)  
 Min - Max 1.4 - 37.0 1.0 - 36.5  
Random 
glucose 
missing 
Yes 14984/21893 (68.4) 14948/21893 (68.3) 0.71 
 No 6909/21893 (31.6) 6945/21893 (31.7)  
Pulse rate/min Missing/Total (%) 11729/21893 (53.57 
%) 
11758/21893 (53.71 
%) 
0.53 
 Mean (SD) 70.5 (11.4) 70.5 (11.0)  
 Median (IQR) 70.0 (62.0 to 78.0) 70.0 (62.0 to 78.0)  
 Min - Max 30.0 - 150.0 37.0 - 150.0  
Pulse missing Yes 11729/21893 (53.6) 11758/21893 (53.7) 0.78 
 No 10164/21893 (46.4) 10135/21893 (46.3)  
EGFR 
(ml/min/m2) 
Missing/Total (%) 13681/21893 (62.49 
%) 
13577/21893 (62.02 
%) 
0.32 
 Mean (SD) 3.6 (0.7) 3.6 (0.7)  
 Median (IQR) 4.0 (3.0 to 4.0) 4.0 (3.0 to 4.0)  
 Min - Max 0.0 - 4.0 0.0 - 4.0  
EGFR missing Yes 13681/21893 (62.5) 13577/21893 (62.0) 0.31 
 No 8212/21893 (37.5) 8316/21893 (38.0)  
Hba1c 
(mmol/mol) 
Missing/Total (%) 11957/21893 (54.62 
%) 
11861/21893 (54.18 
%) 
0.20 
 Mean (SD) 7.7 (1.8) 7.7 (1.8)  
 Median (IQR) 7.2 (6.4 to 8.5) 7.2 (6.4 to 8.6)  
 Min - Max 3.9 - 16.4 2.0 - 18.1  
Hba1c missing Yes 11957/21893 (54.6) 11861/21893 (54.2) 0.36 
 No 9936/21893 (45.4) 10032/21893 (45.8)  
Creatinine 
(Umol/l) 
Missing/Total (%) 11763/21893 (53.73 
%) 
11659/21893 (53.25 
%) 
0.63 
 Mean (SD) 89.7 (29.9) 89.6 (28.9)  
 Median (IQR) 84.0 (73.0 to 98.0) 84.0 (73.0 to 98.0)  
 Min - Max 40.0 - 494.0 40.0 - 485.0  
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Creatinine 
missing 
Yes 11763/21893 (53.7) 11659/21893 (53.3) 0.32 
 No 10130/21893 (46.3) 10234/21893 (46.7)  
 
Legend: Min=minimum Max=maximum SD=Standard Deviation IQR=Interquartile Range 
SIMD=Scottish Index of Multiple Deprivation BP=Blood Pressure EGFR=Estimated 
Glomerular Filtration Rate CI=Confidence Intervals MI=Myocardial Infarction  
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Table 4: Comparison of hazard ratios in depression screened and not screened patient 
groups in existing cardiometabolic disease for the matched data (N=21893 in each 
group).   
Adverse Clinical Outcome HR (with 95% CI) for the depression screened 
vs. not screened group (matched data from 
propensity score) 
All-cause mortality 0.89 (0.84 - 0.93) 
New vascular events (Stroke/MI incidence)                        0.85 (0.78 - 0.91) 
All-cause hospital admissions                   0.95 (0.92 - 0.97) 
Cardiovascular disease related hospital 
admissions                                 
0.92 (0.88 - 0.97) 
Psychiatry unit admissions        0.61 (0.48 - 0.76) 
Cardiovascular disease related mortality 0.85 (0.78 - 0.93) 
 
Legend: HR=Hazard Ratio. CI=Confidence Intervals. MI=Myocardial Depression. Hospital 
Anxiety and Depression Score-Depressive subscale used for depression screening.  
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Table 5 Title: Hazard ratios for clinical outcomes for HADS-D positive compared to the 
HADS-D negative patient groups in existing cardiometabolic disease.   
 Clinical Outcomes Unadjusted Hazard 
Ratio (95% CI) 
Adjusted 
Hazard Ratio 
(95% CI) 
Mild depression (HADS-D 8-
10) 
Moderate/severe depression 
(HADS-D 11-21) 
All-cause mortality 1.35 (1.24 - 1.46) 
 
1.37 (1.25-1.50) 
1.42 (1.31 - 
1.54) 
1.67 (1.52-1.83) 
Mild depression (HADS-D 8-
10) 
Moderate/severe depression 
(HADS-D 11-21) 
CVD related 
mortality 
1.21 (1.05 - 1.39) 
 
1.25 (1.06-1.47) 
1.25 (1.08 - 
1.43) 
1.50 (1.27-1.77) 
Mild depression (HADS-D 8-
10) 
Moderate/severe depression 
(HADS-D 11-21) 
All-Cause hospital 
admissions 
1.27 (1.22 - 1.32) 
 
1.31 (1.26-1.37) 
1.25 (1.20- 
1.30) 
1.35 (1.29-1.42) 
Mild depression (HADS-D 8-
10) 
Moderate/severe depression 
(HADS-D 11-21) 
CVD related 
hospital admissions 
1.34 (1.25 - 1.44) 
 
1.36 (1.25-1.48) 
1.28 (1.19 - 
1.38) 
1.39 (1.28-1.52) 
Mild depression (HADS-D 8-
10) 
Moderate/severe depression 
(HADS-D 11-21) 
Psychiatric unit 
admissions 
1.77 (1.22 - 2.57) 
 
2.25 (1.52-3.32) 
1.73 (1.19 - 
2.52) 
2.19 (1.45-3.30) 
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Mild depression (HADS-D 8-
10) 
Moderate/severe depression 
(HADS-D 11-21) 
New vascular events 
(Stroke/MI) 
1.31 (1.16 - 1.49) 
 
1.22 (1.05-1.41) 
1.28 (1.13 - 
1.45) 
1.29 (1.10-1.51) 
Legend: CI=Confidence Intervals CVD=Cardiovascular Disease MI=Myocardial Infarction 
HADS-D= Hospital Anxiety and Depression Score-Depressive Subscale HADS-D 
positive=HADS-D>7 Adjusted analysis=adjusted for age, sex, deprivation status, number of 
cardiometabolic conditions and initiation of antidepressants. 
 
 
